Bernard R. Perez, M.D., F.A.C.S.
Certification
American Board of Ophthalmology
Education
High School Jesuit High School, Tampa, Florida
Graduated in 1975
College Universidad Central del Este,
San Pedro de Macoris, Dominican Republic
July 1975-August 1977
Major: Pre-Med
Medical School Universidad Central del Este,
San Pedro de Macoris, Dominican Republic
September 1977 - September 1980
Degree: M.D.
Post Graduate Training
Research Fellowship, Cornell University
Catholic Medical Center of
Brooklyn and Queens, Jamaica, NY
Internal Medicine
July 1981 - June 1982
Residency Catholic Medical Center of
Brooklyn and Queens, Jamaica, NY
PGY-2 Ophthalmology
July 1982 - June 1983
Affiliate, Cornell University
Catholic Medical Center of Brooklyn and Queens
Jamaica, NY, (Cornell University)
PGY-3 Ophthalmology
July 1984 - June 1985
Catholic Medical Center of
Brooklyn and Queens, Jamaica, NY
PGY-4 Ophthalmology, Chief Resident
July 1985 - June 1986
Research Fellowship Columbia -
Presbyterian medical Center
Fellowship The Edwards S Harkness Medical Center
July 1982 - April 1983
Hospital Affilations
Active Staff Tampa General Hospital,
University of South Florida, Tampa, FL
Department of Ophthalmology
1986 - Present
Active Staff St. Joseph's Hospital, Tampa, FL
1986 - Present
Active Staff University Community Hospital, Tampa, FL
1986 - Present
Active Staff Tampa Outpatient Surgery, Tampa, FL
1990 - Present
Courtesy H. Lee Moffitt Cancer Center
& Research Institute, Tampa, FL
1995 - Present
Courtesy Town & Country Hospital / IASIS Healthcare,
Tampa, FL, 1986 - Present
Courtesy Vencor Hospital, Tampa, FL
1986 - Present
Health Related Organizations
- Official Ophthalmologist for the NFL, Tampa Bay Buccaneers
- The International Society of Refractive Surgery
- Assistant Clinical Professor, University of South Florida
- American Board of Ophthalmology (Diplomat)
- American Academy of Ophthalmology
- Hillsborough County Medical Association
- Florida Medical Association
- Pan American Association of Ophthalmology
Clinical Research Projects:
Studies of the Molecular Genetics of the Eye: Sponsor: Cleveland Clinic. Sub-Investigator
Multi-Center, Randomized, Double-Masked, Parallel Study to Compare the Safety and Efficacy of 0.3% Gatifoxacin Ophthalmic Solution With That of 0.3% Ofloxacin Ophthalmic Solution in The Treatment of Acute Bacterial Conjunctivitis: SPCL-GFLX 3/02: Sponsor: Senju/Allergan . Principal Investigator
Multicenter, Double-Masked, Randomized, 3-Arm Parallel Study, For 3 Months (With A 9-Month, Masked Extension) Of The Safety And Efficacy Of Bimatoprost 0.03%/Timolol 0.5% Combination Ophthalmic Solution Once Daily Compared With Timolol 0.5% Monotherapy Twice Daily And Bimatoprost 0.03% Monotherapy Once Daily In Patients With Glaucoma Or Ocular Hypertension: 192024-021T: Sponsor: Allergan. Principal Investigator
A Randomized, Multi-Center Comparison of the Aqueous Humor Concentration of Loteprednol Etabonate Following Administration of Bausch & Lomb, Inc Loteprednol Etabonate and Tobramycin Ophthalmic Suspension 0.5%/0.3% or Lotemax® (loteprednol etabonate ophthalmic suspension, 0.5%) During Routine Cataract Surgery. BLP 358-006: Sponsor: Bausch & Lomb, Inc. Sub-Investigator
A Prospective, Multicenter, Open Label Study To Evaluate The Overall Clinical And Patient Acceptance Of The Hyroview“ Hp60m Intraocular Lens In Patients Undergoing Routine Cataract Surgery: HYV2-701 CAT: Sponsor: Bausch & Lomb, Inc. Principal Investigator
A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide (0.5 or 2mg) Implant in Patients with Non Infectious Uveitis Affecting the Posterior Segment of the Eye: BLP 415 - 004: Sponsor: Bausch & Lomb, Inc. Sub-Investigator
A comparison of CIPRODEX (Ciprofloxacin 0.3%, Dexamethasone 0.1%) Ophthalmic Suspension, versus CILOXAN® (Ciprofloxacin 0.3%) Ophthalmic Solution, MAXIDEX ® (Dexamethasone 0.1%) Ophthalmic Suspension and CIPRODEX Vehicle for Treatment of Bacterial Blepharitis: C-02-52: Sponsor: Alcon Research: Principal Investigator
A Three-Month, Randomized, Double-Masked, Paralle Group, Primary Therapy Study with a Planned Nine-Month Extension, of the Safety and IOP-Lowering Efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% Compared to ALPHAGAN®P, 0.15% in Patients with Open-Angle Glaucoma or Ocular Hypertension: C-02-49: Sponsor: Pharmacia, Principal Investigator
Multi-Purpose Solution Comparison Study: #352: Sponsor: Bausch & Lomb, Inc. Sub-Investigator
